Lexaria Bioscience

About:

Lexaria Bioscience Is developes it's DehydraTECH technology that promotes healthy administration methods.

Website: http://lexariabioscience.com/

Twitter/X: lexariacorp

Description:

Lexaria Bioscience Corp. has developed and out-licenses its disruptive and cost-effective DehydraTECH™ technology that promotes healthier administration methods, lower overall dosing and higher effectiveness of ingestible drugs and other beneficial molecules. Lexaria’s DehydraTECHTM delivery technology is protected by a robust suite of patents granted or pending worldwide and is proven effective in multiple international studies in greatly assisting rapidity and quantity of absorption of a range of lipophilic (i.e., fat-soluble), bioactive molecules. By significantly enhancing the performance and experience with oral ingestion, Lexaria’s DehydraTECH delivery technology offers a viable and often healthier alternative to other delivery methods for bioactive substances in widespread use today such as inhalational delivery through smoking.

Total Funding Amount:

$23.9M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Kelowna, British Columbia, Canada

Founded Date:

2004-01-01

Founders:

Number of Employees:

501-1000

Last Funding Date:

2024-10-15

IPO Status:

Public

Industries:

© 2025 bioDAO.ai